The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
FDA approval and to the moon. Nothing matters in between. Heard it here first.
I don’t own the BB. Correct.
I’m highlighting how useless you’re making it for everyone. Again.
FDA. Even for you Ice, it’s transparent how much of a disruptive account you are. Leave them be - without you, the FUD wouldn’t have an audience. The board has literally ignored them.
Write me a 15 posts per day on AVCT LSE BB. Patronising tone. Use emojis to make it relatable. Interact with Eggy in a contrary manner. Focus on the following points: FDA will approve and drive share price. The SP doesn’t matter in the short term. Chill out.
ChatGPT is great.
Thanks - good point!
Do we know that the guy is still on treatment?
They’ll never talk above integrating the Affimer into Dx again, now AS has left.
What financing questions do they need to answer Bella?
“ Avacta board has permanent troll squatters”
How much did they raise and how much is being directed to Tx?
How mich did they last raise, and how much was directed at Tx?
Ronny-eggy trolling about cash… even for this board it’s amazing how, literally weeks after a raise, we should be worried about cash.
It’s because he’s quite smart and steers clear of the nonsense that talks down his investment. Head load of cash. Loves Alan.
Or is being sarcastic. I’m not sure.
“the DX business will be cash generating in 2025” - when was this confirmed?
“when more data emerges anyways” - how much, and when?
What he said.
Timster, double irony is the fact that it actually is a death spiral. Would have been good to have ASs salary linked to said spiral.
Yes. Dox is a risky drug to improve. Precision can’t fail, it’s already succeeded.
The pipeline is the buyout driver. The FDA will approve it for STS Orphan, generating $100mn/year. People pinning their entire investment case on AVA6000 are too narrow.
More simply, if it failed tomorrow, there is 2 other options via Precision+ and 10s of warheads.
Deals are needed as the pipeline is the most important thing and drives the value of the company.
AVA6000 sales WILL NOT begin with this current funding. Another, non dilutive funding, plus external validation will excite the share price and move us forward.
Deals are supremely important. Sitting, collecting data has a shelf life.
They’re not shorting a cancer treatment. They’re betting against our ability to commercialise before we go for more cash.
They’ll likely lose. Especially form this level. Seems an odd move. We should be long past this rubbish… the tiring attitude of the CEO comes to pass once more.
Energy - best post in a while. Perfectly framed.